Uveal Melanoma
Uveal Melanoma is a rare eye cancer with distinct genetic drivers such as GNAQ/GNA11 mutations. Molecular profiling assists in defining targeted treatment approaches.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Uveal Melanoma in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| HLA |
|
Defined at the solid tumor level and applicable to Uveal Melanoma and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Uveal Melanoma. Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
HLA (HLA-A*02:01)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)